Millennium Biotechnologies Retains KCSA Worldwide To Head Full-Service Communications Campaign.

BASKING RIDGE, N.J. -- Millennium Biotechnologies, Inc. (OTCBB: MBTG.OB), a pioneer in the research and development of specialized nutritional products formulated for the medical market, today announced it has retained KCSA Worldwide to implement a comprehensive public relations campaign dedicated primarily to the support of the Company's flagship products, Resurgex(R) and Resurgex Plus(TM).

Commenting on the appointment, Jerry Swon, Sr., president and chief executive said, "This is clearly an exciting time for our Company. We look forward to working with KCSA as we broaden the reach of our products, and communicate our strategy for success to various media outlets, the medical community and the general public.

We are pleased to have in place a communications campaign that supports our unique product line, which has been developed to enhance the nutritional needs and quality of life for patients with immuno-compromised conditions, including HIV/AIDS, Cancer and Hepatitis. We believe our scientifically sound, patented multi-component nutritional formulas offer long-term growth opportunities."

Todd Fromer, managing partner of KCSA Worldwide, said, "We are excited to work with Millennium Biotechnologies. The Company presents a compelling story and management has expressed a strong commitment to increase awareness among core constituents. We look forward to providing our integrated and full service capabilities in support of Millennium's communications initiatives."

About KCSA Worldwide

KCSA Worldwide is a leading public and investor relations firm with practice areas in public relations, investor relations, corporate and marketing communications, and design and graphics. KCSA is the U.S. partner of European Communication Partners, a network of public relations firms in EEC countries and Canada, and the U.S. member of IR Asia-Pacific Ltd., the world's first network of independent investor relations consultancies. The firm has strategic alliances in Australia, Israel, Russia and South America.

About Millennium Biotechnologies

Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies, Group Inc. is a pioneer in the research and development and marketing of medical nutritional supplements. Millennium owns the exclusive rights to RESURGEX(R) and RESURGEX Plus(TM), multiple action nutritional formulas containing the critically important, orally effective form of (SOD)/Gliadin (Defenzyme(TM))) and several other essential nutritional components. Millennium products are designed to assist in increasing energy, maintaining lean muscle, reducing oxidative stress and supporting immune function in patients with HIV/AIDS, Hepatitis C, cancer or other immuno-compromised conditions as an adjunct to their medical care. For more information about Millennium Biotechnologies, Inc., log onto www.milbiotech.com.

This news release contains forward-looking statements that are based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions on the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of Resurgex and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially from those anticipated in such forward-looking statements even if experience or future changes make it clear that any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.